Skip to main content
. 2018 Dec 27;20(1):69–82. doi: 10.3348/kjr.2018.0231

Table 1. Summary of Changes in 8th Edition.

Changes in anatomic stages (T, N, M)
 Clarification of previously ambiguous definitions (T) Maximum dimension of largest tumor is measured not adding satellite foci
Multiple cancers are documented using (m) modifier
Satellite tumor nodules in skin should be separate from main mass to qualify T4b
 Measurement of metastatic lymph node on pathology (N) Pathologic staging of lymph node metastases uses only largest contiguous tumor deposit for pN
 Definition of distant metastasis (M) pM0 is not valid category; cM0, cM1, and pM1 are used
Clarification of post neoadjuvant therapy staging
 After neoadjuvant therapy, ycTNM and ypTNM classification are used
 Response to neoadjuvant chemotherapy is evaluated as complete response, partial response, and no response
Adoption of prognostic staging (Clinical and Pathologic Prognostic Stages)
 Inclusion of biomarkers: tumor grade, hormone receptors, and HER2
 Inclusion of multigene panels (Oncotype DX)
 Clinical Prognostic Stage is assigned to all patients regardless of type of therapy they receive
 Pathologic Prognostic Stage is assigned to patients who receive surgery as initial treatment (excluding patients who receive neoadjuvant chemotherapy)

M = metastasis, N = nodes, pN = pathologic N, T = tumor, TNM = tumor-node-metastasis

HHS Vulnerability Disclosure